CD28 and neoplasm: Therefore, our current dual-targeting BiCisCAR design strategy not only provides both CD28 and 4-1BB co-stimulation signaling for improved T-cell activation, but also allows for simultaneous targeting of two tumor-associated antigens to prevent potential tumor escape.